Neurothera Labs (TSXV:NTLX) Beta: -0.8641 (As of Aug. 12, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSXV:NTLX Neurothera Labs Inc TSXV:NTLX
31 GF Score
Price C$0.33
! 2 Warning Signs
View Full Analysis

What is Neurothera Labs Beta?

Neurothera Labs TSXV:NTLX +12.07% 31 Beta is -0.8641 as of Aug. 12, 2026. GuruFocus rates TSXV:NTLX with a GF Score™ of 31/100. The stock has 2 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-08-12), Neurothera Labs's Beta is -0.8641.


Neurothera Labs  (TSXV:NTLX) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Neurothera Labs Beta Related Terms


Neurothera Labs Beta Historical Data

* Premium members only.

The historical data trend for Neurothera Labs's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neurothera Labs Beta Chart

Neurothera Labs Annual Data
Trend Jan21 Jan22 Jan23 Jan24 Jan25
Beta
0.00 0.00 0.00 0.00 -0.33

Neurothera Labs Quarterly Data
Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Dec25
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.26 -0.33 -0.35 -1.26 -1.39

TSXV:NTLX vs LLY, JNJ, ABBV: Beta Comparison

For the Drug Manufacturers - General subindustry, Neurothera Labs's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Neurothera Labs Beta vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Neurothera Labs's Beta distribution charts can be found below:

* The bar in red indicates where Neurothera Labs's Beta falls into.


TSXV:NTLX
31GF Score
Neurothera Labs Inc TSXV:NTLX
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Neurothera Labs Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of -0.8641 mean?
Neurothera Labs (TSXV:NTLX) has a Beta of -0.8641 as of Aug. 12, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Neurothera Labs and its competitors.
Is Neurothera Labs' Beta too high?
Neurothera Labs' current Beta is -0.8641. Overall, Neurothera Labs has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Neurothera Labs' Beta compare to LLY and JNJ?
Neurothera Labs' Beta of -0.8641 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Drug Manufacturers company?
A good Beta depends on the Drug Manufacturers industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Neurothera Labs and its competitors. Neurothera Labs's current Beta is -0.8641. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neurothera Labs stock overvalued right now?
Neurothera Labs (TSXV:NTLX) has a current Beta of -0.8641. The current Beta is -0.8641. Neurothera Labs' overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Neurothera Labs (TSXV:NTLX), the current Beta is -0.8641 as of Aug. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Neurothera Labs Business Description

Address 325 Front Street West, 2nd Floor, Toronto, ON, CAN, M5V2Y1
Neurothera Labs Inc is a specialty clinical-stage pharmaceutical company. The company's focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid therapies. With this focus, it has been engaged in developing and testing pharmaceutical compositions comprised of N-acylethanolamines, CBD and/or other cannabinoid receptors agonists. The Company is currently engaged in development programs based on tetrahydrocannabinol and/or non-psychoactive cannabidiol for the treatment of Tourette syndrome, Alzheimer's disease and agitation, autism spectrum disorder and Status Epilepticus.
31GF Score

Get the complete analysis for TSXV:NTLX

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$0.33
Price